Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA4 | P43681 | 6/20 | 0.54 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | SCD | O00767 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3336984 | 0.94 | CHRNA4 (0.53) | CHRNA4USP30ACACBSCDLMNA | |
| SCHEMBL3338954 | 0.89 | CHRNA4 (0.50) | CHRNA4USP30ACACBSCD | |
| SCHEMBL3334936 | 0.87 | CHRNA4 (0.48) | CHRNA4USP30SCDLMNASCD5 | |
| SCHEMBL3331007 | 0.84 | CHRNA4 (0.51) | CHRNA4USP30 | |
| SCHEMBL3337068 | 0.84 | CHRNA4 (0.51) | CHRNA4 | |
| SCHEMBL3332944 | 0.84 | CHRNA4 (0.49) | CHRNA4USP30SCDSCD5 | |
| SCHEMBL3339863 | 0.81 | CHRNA4 (0.64) | CHRNA4USP30 | |
| SCHEMBL3335848 | 0.81 | CHRNA4 (0.70) | CHRNA4USP30SCDLMNASCD5 | |
| SCHEMBL3341400 | 0.80 | CHRNA4 (0.62) | CHRNA4USP30 | |
| SCHEMBL3333206 | 0.79 | CHRNA4 (0.53) | CHRNA4USP30ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144700-A1 | HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS | TARGACEPT, INC. (US) | 2010-06-10 | — | — | US | claimed |
| US-20100144700-A1 | HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS | TARGACEPT, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| WO-2008112734-A1 | HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS | TARGACEPT, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144700-A1 | HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS | CHRNA10, CHRNA2, CHRNE | CHRNA4 8/4885USP30 4404/4885ACACB 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.